Evidence map›Paper›PMID 27803322›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

S2 from equine infectious anemia virus is an infectivity factor which counteracts the retroviral inhibitors SERINC5 and SERINC3.

Ajit Chande, Emilia Cristiana Cuccurullo, Annachiara Rosa, Serena Ziglio, Susan Carpenter, Massimo Pizzato

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.

0numbers the graph read from it
0cells of the map it votes in
68citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

68 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. EIAV encodes an accessory protein that antagonizes the host restriction factor equine tetherin.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. SERINC5 counters retroviruses and non-retroviruses.Frontiers in cellular and infection microbiology · 2024
    Review
  12. Article
  13. Review
  14. Article
  15. HIV-1 restriction by SERINC5.Medical microbiology and immunology · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

8 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Ajit ChandeCentre for Integrative Biology, University of Trento, 38123 Trento, Italy.
Emilia Cristiana CuccurulloCentre for Integrative Biology, University of Trento, 38123 Trento, Italy.
Annachiara RosaCentre for Integrative Biology, University of Trento, 38123 Trento, Italy.
Serena ZiglioCentre for Integrative Biology, University of Trento, 38123 Trento, Italy.
Susan CarpenterDepartment of Animal Science, Iowa State University, Ames, IA 50011.
Massimo PizzatoCentre for Integrative Biology, University of Trento, 38123 Trento, Italy; massimo.pizzato@unitn.it.ORCID 0000-0002-9491-1483
University of Trento · ITIowa State University · US

Funding

Strategies of lentivirus persistenceR01CA128568 · NCI · WASHINGTON STATE UNIVERSITY · PI CARPENTER, SUSAN · 2008 to 2012
$1.5M
NCI NIH HHS R01 CA128568
6 · The paper itself

Abstract

The lentivirus equine infectious anemia virus (EIAV) encodes the small protein S2, a pathogenic determinant that is important for virus replication and disease progression in horses. No molecular function had been linked to this accessory protein. We report that S2 can replace the activity of Negative factor (Nef) in HIV-1 infectivity, being required to antagonize the inhibitory activity of Serine incorporator (SERINC) proteins on Nef-defective HIV-1. Like Nef, S2 excludes SERINC5 from virus particles and requires an ExxxLL motif predicted to recruit the clathrin adaptor, Adaptor protein 2 (AP2). Accordingly, functional endocytic machinery is essential for S2-mediated infectivity enhancement, and S2-mediated enhancement is impaired by inhibitors of clathrin-mediated endocytosis. In addition to retargeting SERINC5 to a late endosomal compartment, S2 promotes host factor degradation. Emphasizing the similarity with Nef, we show that S2 is myristoylated, and, as is compatible with a crucial role in posttranslational modification, its N-terminal glycine is required for anti-SERINC5 activity. EIAV-derived vectors devoid of S2 are less susceptible than HIV-1 to the inhibitory effect of both human and equine SERINC5. We then identified the envelope glycoprotein of EIAV as a determinant that also modulates retroviral susceptibility to SERINC5, indicating that EIAV has a bimodal ability to counteract the host factor. S2 shares no sequence homology with other retroviral factors known to counteract SERINC5. Like the primate lentivirus Nef and the gammaretrovirus glycoGag, the accessory protein from EIAV is an example of a retroviral virulence determinant that independently evolved SERINC5-antagonizing activity. SERINC5 therefore plays a critical role in the interaction of the host with diverse retrovirus pathogens.

Indexed as

Membrane ProteinsNeoplasm ProteinsReceptors, Cell SurfaceViral ProteinsVirulence FactorsCell LineHIV-1HumansInfectious Anemia Virus, EquineMembrane GlycoproteinsVirus ReplicationMembrane GlycoproteinsMembrane ProteinsNeoplasm ProteinsReceptors, Cell SurfaceS2 protein, Equine infectious anemia virusSERINC3 protein, humanSERINC5 protein, humanViral ProteinsVirulence Factorsrestriction factorretrovirusvirus infection

Identifiers

PMID27803322
PMCPMC5135340
OpenAlexW2548462455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.